Various drug delivery approaches to the central nervous system

Expert Opinion on Drug Delivery

Volumn 7, Issue 1, 2010, Pages 113-135

  Pasha, Santosh ^a   Gupta, Kshitij ^b  

^a CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Blood brain barrier; Brain targeting; Central nervous system; Colloidal nanosystems; Convection enhanced delivery; Delivery approaches

Indexed keywords

ALPHA METHYLHISTAMINE; CARRIER PROTEIN; CELL PENETRATING PEPTIDE; CODEINE; DEFEROXAMINE; DENDRIMER; DIAMORPHINE; ENKEPHALIN; ESTRADIOL; ETHOXZOLAMIDE; FLURBIPROFEN; GLUCOSE TRANSPORTER 1; GLYCOPROTEIN P; INDOMETACIN; INSULIN; KETOPROFEN; MULTIDRUG RESISTANCE PROTEIN; NEUROPROTECTIVE AGENT; NEUROTROPHIN; NIPECOTIC ACID; POLYMER; PROGESTERONE; RECOMBINANT ERYTHROPOIETIN; SOLID LIPID NANOPARTICLE; SOMATOMEDIN C; TACRINE;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BRAIN HEMORRHAGE; BRAIN INJURY; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CONVULSION; DEGENERATIVE DISEASE; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; EPILEPSY; HUMAN; LIPOSOMAL DELIVERY; MICELLE; NONHUMAN; OLFACTORY SYSTEM; REVIEW;

AMINO ACID SEQUENCE; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DRUG DELIVERY SYSTEMS; ENKEPHALIN, METHIONINE; FMRFAMIDE; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS;

EID: 73649126581     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240903405581     Document Type: Review

References (144)

1. Begley DJ, Brightman MW. Structural and functional aspects of the blood-brain barrier. In: Prokai L, Prokai-Tatrai K, editors. Basel: Birkhauser Verlag; 2003
2. Pavan B, Dalpiaz A, Ciliberti N, et al. Progress in drug delivery to the central nervous system by the prodrug approach. Molecules 2008;13:1035-1065
3. Misra A, Ganesh S, Shahiwala A, Shrenik P. Shah. Drug delivery to the central nervous system: a review. J Pharm Pharmaceut Sci 2003 6(2):252-273
4. Pardridge WM. Brain drug targeting: the future of brain drug development. Cambridge: CPU; 2001
5. Deeken JF, Löscher W. The Blood-brain barrier and cancer: transporters, treatment, and trojan horses. Clin Cancer Res 2007;13:1663-1674
6. Barbu E, Molnàr E, Tsibouklis J, Górecki DC. The potential for nanoparticle-based drug delivery to the brain: overcoming the blood-brain barrier. Expert Opin Drug Deliv 2009;6(6):553-565
7. Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 2004;104:29-45
8. Pardridge WM. Blood-brain barrier delivery. Drug Discov Today 2007; 12(1-2):54-61
9. Begley DJ. ABC transporters and the blood-brain barrier. Curr Pharm Des 2004;10(12):1295-1312
10. Witt KA, Gillespie TJ, Huber JD, et al. Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability. Peptides 2001;22:2329-2343
11. Banks WA. The CNS as a target for peptides and peptide-based drugs. Expert Opin Drug Deliv 2006;3(6):707-712
12. Pignatello R, Pantò V, Salmaso S, et al. Flurbiprofen derivatives in alzheimer's disease: synthesis, pharmacokinetic and biological assessment of lipoamino acid prodrugs. Bioconjug Chem 2008;19:349-357
13. Krause M, Stark H, Schunack W. Azomethine prodrugs of (R)-alpha-methylhistamine, a highly potent and selective histamine H3-receptor agonist. Curr Med Chem 2001;8:1329-1340
14. Lecomte JM, Costentin J, Vlaiculescu A, et al. Pharmacological properties of acetorphan, a parentererally active 'enkephalinase' inhibitor. J Pharmacol Exp Ther 1986;237:937-944
15. Yoshiharu D, Hideki H, Shinobu F, et al. Improved brain delivery of a nonsteroidal anti-inflammatory drug with a synthetic glyceride ester: a preliminary attempt at a CNS drug delivery system for therapy of alzheimer's disease. J Drug Target 2000;8:371-381
16. Nassereddine-Sebaei M, Crider AM, Carroll RT, Hinko CN. Determination of m nitrophenol and nipecotic acid in mouse tissues by high-performance liquid chromatography after administration of the anticonvulsant m-nitrophenyl piperidinecarboxylate hydrochloride. J Pharm Sci 1993;82:39-43
17. Tao G, Yuan H, Zhi-rong Z, Li-li L. Synthesis and characterization of 9-[P(N,Ndipropylsulfamide)] benzoylamino-1,2,3,4-4H-acridine. A potential prodrug for the CNS delivery of tacrine. J Drug Target 2004;12:177-182
18. Dvir E, Elman A, Simmons D, et al. DP-155, a lecithin derivative of indomethacin, is a novel nonsteroidal antiinflammatory drug for analgesia and Alzheimer's disease therapy. CNS Drug Rev 2007;13:260-277
19. Hanif K, Gupta K, Gupta S, et al. Chimeric peptide of met-enkephalin and FMRFa: effect of chlorination on conformation and analgesia. Neurosci Lett 2006;403(1-2):131-135
20. Bodor N, Prokai L,Wu W-M, et al. A strategy for delivering peptides into the central nervous system by sequential metabolism. Science 1992;257:1698-1700
21. Sipple W. Computational approaches for the prediction of blood brain barrier permeation. Curr Med Chem Cent Nerv Syst Agents 2002; 2:211-227
22. Tsuji A. Specific mechanisms for transporting drugs into brain. In: Begley DJ, Bradbury MW, Kreuter J, editors, The blood-brain barrier and drug delivery to the CNS. New York: Dekker; 2000
23. Chishty M, Begley DJ, Abbott NJ, Reichel A. Interaction of nucleoside analogues with nucleoside transporters in rat brain endothelial cells. J Drug Target 2004;12:265-272
24. Smith QR, Stoll J. Molecular characterization of amino acid transporters at the blood-brain barrier. In: Paulson OB, Moos Knudsen G, Moos T, editors, Brain barrier systems. Alfred Benzon Symposium Copenhagen: Munksgaard; 1999
25. Gomes P, Soares-da-Silva P. L-DOPA transport properties in an immortalised cell line of rat capillary cerebral endothelial cells, RBE 4. Brain Res 1999;829(1-2):143-150 (Pubitemid 29251694)
26. Rautio J, Laine K, Gynther M, Savolainen J. Prodrug approaches for CNS delivery. AAPS J 2008;10(1):92-102
27. Bilsky E, Egleton RD, Mitchell SA, et al. Enkephalin glycopeptide analogues produce analgesia with reduced dependence liability. J Med Chem 2000;43:2586-2590
28. Masand G, Hanif K, Sen S, et al. Synthesis, conformational and pharmacological studies of glycosylated chimeric peptides of Met-enkephalin and FMRFa. Brain Res Bull 2006;68(5):329-334
29. Hokari M, Wu HQ, Schwarcz R, Smith QR. Facilitated brain uptake of 4-chlorokynurenine and conversion to 7-chlorokynurenic acid. Neuroreport 1996;8(1):15-18
30. Gynther M, Laine K, Ropponen J, et al. Large neutral amino acid transporter enables brain drug delivery via prodrugs. J Med Chem 2008;51:932-936
31. More SS, Vince R. Design, synthesis and biological evaluation of glutathione peptidomimetics as components of anti-parkinson prodrugs. J Med Chem 2008;51:4581-4588
32. Manfredini S, Pavan B, Vertuani S, et al. Design, synthesis and activity of ascorbic acid prodrugs of nipecotic, kynurenic and diclophenamic acids, liable to increase neurotropic activity. J Med Chem 2002;45:559-562
33. Guo P, Ma J, Li S, et al. Targeted delivery of a peripheral benzodiazepine receptor ligand gemcitabine conjugate to brain tumors in a xenograft model. Cancer Chemother Pharmacol 2001;48:169-176
34. Brasnjevic I, Steinbusch HW, Schmitz C, Martinez-Martinez P. Delivery of peptide and protein drugs over the blood-brain barrier. Prog Neurobiol 2009;87:212-251
35. Bickel U, Kang YS, Yoshikawa T, Pardridge WM. In vivo demonstration of subcellular localization of antitransferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. J Histochem Cytochem 1994;42:1493-1497
36. Broadwell RD, Balin BJ, Selcman M. Transcytotic pathways for blood-bourne protein through the blood-brain barrier. Proc Natl Acad Sci USA 1998;85:632-636
37. Pardridge WM, Triguero D, Buciak, et al. Evaluation of cationized rat albumin as a potential blood-brain barrier drug transport vector. J Pharmacol Exp Ther 1990;255:893-899
38. Begley DJ. Efflux mechanisms in the central nervous system: a powerful influence on drug distribution within the brain. In: Sharma HS, Westman J, editors, Blood-spinal cord and brain barriers in health and disease. San Diego: Elsevier; 2004
39. Sauna ZE, Ambudkar SV. Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein. The two ATP hydrolysis events in a single catalytic cycle are kinetically similar but affect different functional outcomes. J Biol Chem 2001;276:11653-11661
40. Litman T, Skousgaard T, Stein WD. Pumping of drugs by P-glycoprotein: a two step process? J Pharm Exp Ther 2003;307:846-853
41. Kabanov A, Batrakova E, Miller D. Pluronic block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier. Adv Drug Deliv Rev 2003;55:151-164
42. Wadia JS, Dowdy SF. Protein transduction technology. Curr Opin Biotechnol 2002;13:52-56
43. Zhao M, Weissleder R. Intracellular cargo delivery using Tat peptide and derivatives. Med Res Rev 2004; 24:1-12
44. Rousselle C, Clair P, Lefauconnier J-M, et al. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol Pharmacol 2000;57:679-686
45. Richard JP, Melikov K, Vives E, et al. Cell penetrating peptides: a re-evaluation of the mechanism of cellular uptake. J Biol Chem 2003;278:585-590
46. Rousselle C, Smirnova M, Clair P, et al. Enhanced delivery of doxorubicin into the brain via a peptidevector-mediated strategy: saturation kinetics and specificity. J Pharmacol Exp Ther 2001;296:124-131
47. Lindgren M, Hällbrink M, Prochiantz A, Langel U. Cell penetrating peptides. Trends Pharmacol Sci 2000;21:99-103
48. Torchilin VP, Rammohan R, Weissig V, Levchenko TS. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci 2001;98:8786-8791
49. Fawell S, Seery J, Daikh Y, et al. Tat-mediated delivery of heterologous protein into cells. Proc Natl Acad Sci USA 1994;91:664-668
50. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein in the mouse. Science 1999;285:1569-1572
51. Cao G, Pei W, Ge H, et al. In vivo delivery of a Bcl-XL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J Neurosci 2002;22:5423-5431
52. Kilic E, Dietz GP, Hermann DM, Bahr M. Intravenous TAT-Bcl-XL is protective after middle cerebral artery occlusion in mice. Ann Neurol 2002;52:617-622
53. Rousselle C, Smirnova C, Clair P, et al. Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: saturation kinetics and specificity. J Pharmacol Exp Ther 2001:296:124-131
54. Rousselle C, Clair P, Lefauconnier JM, et al. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol Pharmacol 2000;57(4):679-686
55. Rapoport SI. Osmotic opening of the blood-brain barrier: principles mechanism and therapeutic applications. Cell Mol Neurobiol 2000;20:217-230
56. Erdlenbruch B, Schinkhof C, Kugler W, et al. Intracarotid administration of shortchain alkylglycerols for increased delivery of methotrexate to the rat brain. Br J Pharmacol 2003;139:685-694
57. Kaya M, Chang L, Truong A, Brightman MW. Chemical induction of fenestrae in vessels of the blood-brain barrier. Exp Neurol 1996;142:6-13 (Pubitemid 26381376)
58. Rabchevsky AG, Degos JD, Dreyfus PA. Peripheral injections of freund's adjuvant in mice provoke leakage of serum proteins through the blood-brain barrier without inducing reactive gliosis. Brain Res 1999;832:84-96
59. Chio CC, Baba T, Black KL. Selective blood-tumor barrier disruption by leukotrienes. J Neurosurg 1992;77:407-410
60. Emerich DF, Dean RL, Osborn C, Bartus RT. The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood-brain barrier: from concept to clinical evaluation. Clin Pharmacokinet 2001;40:105-123
61. Emerich DF, Dean RL, Marsh J, et al. Intravenous cereport (RMP-7) enhances delivery of hydrophilic chemotherapeutics and increases survival in rats with metastatic tumors in the brain. Pharm Res 2000;17(10):1212-1218
62. Schirmacher A, Winters S, Ficher S, et al. Electromagnetic fields (1.8 GHz) increases the permeability to sucrose of the blood-brain barrier in vitro. Bioelectromagnetics 2000;21:338-345
63. Cho C-W, Liu Y, Cobb WN, et al. Ultrasound-induced mild hyperthermia as a novel approach to increase drug uptake in brain microvessel endothelial cells. Pharm Res 2002;19:1123-1129
64. Garcia-Garcia E, Andrieux K, Gil S, Couvreur P. Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain? Int J Pharm 2005;298:274-292
65. Tosi G, Costantino L, Ruozi B, et al. Polymeric nanoparticles for the drug delivery to the central nervous system. Exp Opin Drug Deliv 2008;5(2):155-174
66. Ricci M, Blasi P, Giovagnoli S, Rossi C. Delivering drugs to the central nervous system: a medicinal chemistry or a pharmaceutical technology issue? Curr Med Chem 2006;13:1707-1725
67. Kabanov AV, Batrakova EV. New Technologies for drug delivery across the blood brain barrier. Curr Pharm Des 2004;10:1355-1363
68. Townsend SA, Evrony GD, Gu FX, et al. Tetanus toxin C fragment-conjugated nanoparticles for targeted drug delivery to neurons. Biomaterials 2007;28(34):5176-5184
69. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001;47:65-81
70. Barchet TM, Amiji MM. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases. Expert Opin Drug Deliv 2009;6(3):211-225
71. Denora N, Trapani A, Laquintana V, et al. Recent advances in medicinal chemistry and pharmaceutical technology-strategies for drug delivery to the brain. Curr Top Med Chem 2009;9(2):182-196
72. McClean S, Prosser E, Meehan E, et al. Binding and uptake of biodegradable poly-lactide micro and nanoparticles in intestinal epithelia. Eur J Pharm Sci 1998;6(2):153-163
73. Kreuter J. Nanoparticles as drug delivery systems. In: Nalwa HS, editor, Encyclopedia of pharmaceutical technology. Stevenson Ranch, USA: AmericanScientific Publishers; 2004. p. 161-180
74. Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev 2006;58(14):1532-1555
75. Lockman PR, Koziara JM, Mumper RJ, Allen DD. Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J Drug Target 2004;12(9-10):635-641
76. Calvo JP, Gouritin B, Chacun H, et al. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res 2001;18:1157-1166 (Pubitemid 32900402)
77. Wang AZ, Gu F, Zhang L, et al. Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin Biol Ther 2008;8(8):1063-1070
78. Tosi G, Costantino L, Rivasi F, et al. Targeting the central nervous system: In vivo experiments with peptide-derivatized nanoparticles loaded with loperamide and rhodamine-123. J Control Release 2007;122:1-9
79. Kreuter J, Alyautdin RN, Kharkevich D, Ivanov AA. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles), Brain Res 1995;674:171-174
80. Soni V, Kohli DV, Jain SK. Transferrin-conjugated liposomal system for improved delivery of 5-fluorouracil to brain. J Drug Target 2008;16:73-78
81. Kreuter J, Shamenkov D, Petrov V, et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target 2002;10:317-325
82. Sun W, Xie C, Wang H, Hu Y. Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain. Biomaterials 2004;25:3065-3071
83. Puri A, Kramer-Marek G, Campbell-Massa R, et al. HER2-specific affibody-conjugated thermosensitive liposomes (affisomes) for improved delivery of anticancer agents. J Liposome Res 2008;18(4):293-307
84. Doi A, Kawabata S, Iida K, et al. Tumor-specific targeting of sodium borocaptate (BSH) to malignant glioma by transferrin-PEG liposomes: a modality for boron neutron capture therapy. J Neurooncol 2008;87:287-294
85. Pang Z, Lu W, Gao H, et al. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. J Control Release 2008;128(2):120-127
86. Ko YT, Bhattacharya R, Bickel U. Liposome encapsulated polyethylenimine/ ODN polyplexes for brain targeting. J Control Release 2009;133(3):230-237
87. Du J, Lu WL, Ying X, et al. Dual-Targeting Topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals. Mol Pharm 2009;6(3):905-917
88. Feng B, Tomizawa K, Michiue H, et al. Delivery of sodium borocaptate to glioma cells using immunoliposome conjugated with anti-EGFR antibodies by ZZ-His. Biomaterials 2009;30(9):1746-1755
89. Gupta B, Levchenko TS, Torchilin VP. TAT Peptide-modified liposomes provide enhanced gene delivery intracranial human brain tumor xenografts in nude mice. Oncol Res 2007;16:351-359
90. Qin J, Chen DW, Hu, et al. Surface modification of RGD-liposomes for selective drug delivery to monocytes/ neutrophils in brain. Chem Pharm Bull 2007;55:1192-1197
91. Wilson B, Samanta MK, Santhi K, et al. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat alzheimer's disease. Brain Res 2008;1200:159-168
92. Gupta K, Singh VP, Kurupati RK, et al. Nanoparticles of cationic chimeric peptide and sodium polyacrylate exhibit striking antinociception activity at lower dose. J Control Release 2009;134(1):47-54
93. Agyare EK, Curran GL, Ramakrishnan M, et al. Development of a smart nano-vehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in alzheimer's disease and cerebral amyloid angiopathy. Pharm Res 2008;25(11): 2674-2684
94. Wang X, Chi N, Tang X. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Eur J Pharm Biopharm 2008;70(3):735-740
95. Béduneau A, Hindré F, Clavreul A, et al. Brain targeting using novel lipid nanovectors. J Control Release 2008;126:44-49
96. Blasi P, Giovagnoli S, Schoubben A, et al. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev 2007;59:454-477
97. Yang S, Zhu J, Lu Y, Yang C. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res 1999;16:751-757
98. Zara GP, Cavalli R, Bargoni A, et al. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J Drug Target 2002;10:327-335
99. Wong HL, Bendayan R, Rauth AM, et al. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev 2007;59:491-504
100. Hassan EE, Gallo JM. Targeting anticancer drugs to the brain. I: Enhanced brain delivery of oxantrazole following administration in magnetic cationic microspheres. J Drug Target 1993;1:7-14
101. Batrakova EV, Vinogradov SV, Robinson SM, et al. Polypeptide point modifications with fatty acid and amphiphilic block copolymers for enhanced brain delivery. Bioconjug Chem 2005;16:793-802
102. Liu L, Guo K, Lu J, et al. Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. Biomaterials 2008;29:1509-1517
103. Liu L, Venkatraman SS, Yang YY, et al. Polymeric micelles anchored with TAT for delivery of antibiotics across the blood-brain barrier. Biopolymers 2008;90:617-623
104. Yáñez JA, Forrest ML, Ohgami Y, et al. Pharmacometrics and delivery of novel nanoformulated PEG-b-poly (epsilon-caprolactone) micelles of rapamycin. Cancer Chemother Pharmacol 2008;61:133-144
105. Huang RQ, Qu YH, Ke WL, et al. Efficient gene delivery targeted to the brain using a transferrin conjugated polyethyleneglycol-modified polyamidoamine dendrimer. FASEB J 2007;21:1117-1125
106. Dhanikula RS, Argaw A, Bouchard JF, Hildgen P. Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy and and intratumoral transport capability. Mol Pharm 2008;5:105-106
107. Krewson CE, Klarman ML, Saltzman WM. Distribution of nerve growth factor following direct delivery into brain interstitium. Brain Res 1995;680:196-206
108. Cserr H, Patlak CS. Secretion and bulk flow of interstitial fluid. In: Bradbury MWB, editor, Physiology and pharmacology of the blood-brain barrier. Handbook of experimental pharmacology. Vol.103. Berlin: Springer-Verlag; 1992
109. Illum L. Nasal drug delivery possibilities, problems and solutions. J Control Release 2003;87:187-98
110. The transport of a drug to the cerebrospinal fluid directly from the nasal cavity: the relation to the lipophilicity of the drug. Chem Pharm Bull 1991;39:1458-2456
111. Sakane T, Akizuki M, Taki Y, et al. Direct drug transport from the rat nasal cavity to the cerebrospinal fluid: the relation to the molecular weight of drugs. J Pharm Pharmacol 1995;47:379-381
112. Kao HD, Traboulsi A, Itoh S, et al. Enhancement of the systemic and CNS specific delivery of L-Dopa by the nasal administration of its water soluble prodrug. Pharm Res 2000;17:978-984
113. Wang X, He H, Leng W, Tang X. Evaluation of brain-targeting for the nasal delivery of estradiol by the microdialysis method. Int J Pharm 2006;317:40-46
114. Hanson LR, Frey WH II. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 2008;10:(9 Suppl 3):S5
115. Perez Velazquez JL. Bicarbonate-dependent depolarizing potentials in pyramidal cells and interneurons during epileptiform activity. Eur J Neurosci 2003;18(5):1337-1342
116. Gibson CL, Gray LJ, Bath PM, Murphy SP. Progesterone for the treatment of experimental brain injury; a systematic review'. Brain 2008;131:318-328
117. Kao HD, Traboulsi A, Itoh S, et al. Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs. Pharm Res 2000;17(8):978-984
118. Wang X, He H, Leng W, Tang X. Evaluation of brain-targeting for the nasal delivery of estradiol by the microdialysis method. Int J Pharm 2006;317(1):40-46
119. de Rosa R, Garcia AA, Braschi C, et al. Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc Natl Acad Sci USA 2005;102:3811-3816
120. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH II. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004;127:481-496
121. Hanson LR, Roeytenberg A, Martinez PM, et al. Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. J Pharmacol Exp Ther 2009;330(3):679-686
122. Yu YP, Xu QQ, Zhang Q, et al. Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia. Neurosci Lett 2005;387(1):5-10
123. Matsuoka Y, Gray AJ, Hirata-Fukae C, et al. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci 2007;31:165-170
124. Reger MA, Watson GS, Green PS, et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis 2008;13(3):323-331
125. Allard E, Passirani C, Benoit JP. Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials 2009;30(12):2302-2318
126. Bobo RH, Laske DW, Akbasak A, et al. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 1994;91(6):2076-2080
127. Rousseau J, Boudou C, Barth RF, et al. Enhanced survival and cure of F98 glioma-bearing rats following intracerebral delivery of carboplatin in combination with photon irradiation. Clin Cancer Res 2007;13(17):5195-5201
128. Vandergrift WA, Patel SJ, Nicholas JS, Varma AK. Convection-enhanced delivery of immunotoxins and radioisotopes for treatment of malignant gliomas. Neurosurg Focus 2006;20(4):E13
129. Muro K, Das S, Raizer JJ. Convection-enhanced and local delivery of targeted cytotoxins in the treatment of malignant gliomas. Technol Cancer Res Treat 2006;5(3):201-213
130. Saito R, Bringas JR, Panner A, et al. Convection-enhanced delivery of tumor necrosis factor-related apoptosis inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model. Cancer Res 2004;64(19):6858-6862
131. Nguyen JB, Sanchez-Pernaute R, Cunningham J, Bankiewicz KS. Convection enhanced delivery of AAV-2 combined with heparin increases TK gene transfer in the rat brain. Neuroreport 2001;12(9):1961-1964
132. Perlstein B, Ram Z, Daniels D, et al. Convection-enhanced delivery of maghemite nanoparticles: increased efficacy and MRI monitoring. Neuro Oncol 2008;10(2):153-161
133. Yang W, Barth RF, Wu G, et al. Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumors. J Neurooncol 2009;95(3):355-365
134. Tomoo Inoue, Yoji Yamashita, Masamichi Nishihara, et al. Therapeutic efficacy of a polymeric micellar doxorubicin infused by convection-enhanced delivery against intracranial 9L brain tumor models. Neuro Oncol 2009;11(2):151-157
135. Rogawski MA. Convection-enhanced delivery in the treatment of epilepsy. Neurotherapeutics 2009;6(2):344-351
136. Gasior M, White NA, Rogawski MA. Prolonged attenuation of amygdala-kindled seizure measures in rats by convection-enhanced delivery of the N-type calcium channel antagonists omega-conotoxin GVIA and omega-conotoxin MVIIA. J Pharmacol Exp Ther 2007;323:458-468
137. Querbes W, Ge P, Zhang W, et al. Direct CNS Delivery of siRNA mediates robust silencing in oligodendrocytes. Oligonucleotides 2009;19(1):23-30
138. Oh S, Ohlfest JR, Todhunter DA, et al. Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery. J Neurooncol 2009;95(3):331-342
139. Goldberg L, Ocherashvilli A, Daniels D, et al. Salirasib (farnesyl thiosalicylic acid) for brain tumor treatment: a convection-enhanced drug delivery study in rats. Mol Cancer Ther 2008;7(11):3609-3616
140. Krauze MT, Noble CO, Kawaguchi T, et al. Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (doxil) in rodent intracranial brain tumor xenografts. Neuro Oncol 2007;9(4):393-403
141. Grahn AY, Bankiewicz KS, Dugich-Djordjevic M, et al. Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience. J Neuorooncol 2009;95(2):185-197
142. Saito R, Krauze MT, Noble CO, et al. Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. Neuro Oncol 2006;8(3):205-214
143. Yamashita Y, Krauze MT, Kawaguchi T, et al. Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. Neuro Oncol 2007;9(1):20-28
144. Allard E, Hindre F, Passirani C, et al. 188Re-loaded lipid nanocapsules as a promising radiopharmaceutical carrier for internal radiotherapy of malignant gliomas. Eur J Nucl Med Mol Imaging 2008;35(10):1838-1846